Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
Philipp Haselmayer(Merck KGaA, Darmstadt (Germany)), Roland Grenningloh(Merck KGaA, Darmstadt (Germany))
Cited by 145
Related Papers
Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies
|Frontiers in Immunology|2014|38